Compare Global X FTSE Southeast Asia ETF (ASEA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs Revvity Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $20.75, while Revvity Inc trades at $111.77 (market cap $12.53B). The key difference: Revvity Inc pays a 0.25% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Revvity Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | RVTY | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $20.65 | $117.75 |
52-Week Low | $16.31 | $82.26 |
Market Cap | — | $12.53B |
Enterprise Value | — | $15.02B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $20.65, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong momentum with an ADX of 49.11 indicating a trending market. Recent corporate actions include a declared dividend of $0.41 per share scheduled for July 2026. Key support and resistance levels are clustered around $20-$21, suggesting a critical price zone for near-term direction.
The outlook remains cautiously optimistic given technical strength, but fundamental data is currently unavailable for a complete assessment. Risks include potential volatility near key technical levels and reliance on future financial performance disclosures. Investors should await upcoming earnings reports for clarity on valuation and profitability metrics.
Revvity (RVTY) trades at $112.29, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key support at $110. The company demonstrates consistent earnings beats with Q1 2026 EPS of $1.06 exceeding expectations, maintaining solid profitability with 54.32% gross margins. Recent developments include AI integration partnerships with Anthropic and FDA clearance for new diagnostic tests, signaling innovation in life sciences.
RVTY presents a mixed outlook with analyst consensus leaning bullish (52% buy ratings) but trading above the $109.38 price target. While strong operational cash flow ($583M in 2025) and AI expansion provide upside potential, elevated P/E ratio (53.99) and declining net cash flow (-$243M in 2025) warrant caution amid competitive pressures in healthcare technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
